Top 2 Health Care Stocks That May Crash This Quarter

by | Mar 4, 2026 | General

As of March 4, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

Here’s the latest list of major overbought players in this sector.

Anika Therapeutics Inc (NASDAQ:ANIK)

  • On Feb. 26, Anika Therapeutics reported better-than-expected fourth-quarter financial results. “We closed 2025 with a strong fourth quarter, with top‑line growth led by our Commercial Channel and company‑wide results that included expanded gross margin, and positive operating income and free cash flow,” said Steve Griffin, President and Chief Executive Officer of Anika Therapeutics. “Our operating income performance in the fourth quarter and full year underscores the strength of our core OA Pain Management business despite U.S. pricing headwinds in 2025 and establishes a foundation for improved profitability.” The company’s stock gained around 31% over the past five days and has a 52-week high of $17.56.
  • RSI Value: 87.8                                
  • ANIK Price Action: Shares of Anika Therapeutics gained 0.6% to close at $14.40 on Tuesday.
  • Edge Stock Ratings: 73.53 Momentum score.

Arcellx Inc (NASDAQ:ACLX)

  • On Feb. 23, Arcellx announced it will be acquired by Gilead Sciences. “The story of Arcellx is one of innovation, passion, resilience and teamwork. I could not be prouder of our team, our contribution to the myeloma field, and the impact anito-cel and our D-Domain platform are poised to have for patients and clinicians,” said Rami Elghandour, Chairman and Chief Executive Officer, Arcellx. “We are fortunate to have found a world-class partner in Gilead, which has the expertise to carry forward Arcellx’s legacy. Kite is well-positioned to maximize access to anito-cel, benefiting more patients, and the company’s commitment to be the leader in cell therapy is one I admire. I’m grateful to our Board of Directors for this opportunity, our shareholders who supported our journey, our partners who believed in us, the patients and physicians who participated in our studies, and most of all, our team members who did the impossible and left an indelible mark on the future of medicine.” The company’s stock gained around 64% over the past month and has a 52-week high of $114.38.
  • RSI Value: 83.7
  • ACLX Price Action: Shares of Arcellx closed at $114.05 on Tuesday.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock